The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sulfonylureas are an effective and inexpensive treatment for type 2 diabetes. There is conflicting data about the safety of these drugs regarding mortality and cardiovascular outcomes. The objective of the present study was to evaluate the safety of the sulfonylureas most frequently used and to use trial sequential analysis (TSA) to analyze whether the available sample was powered enough to support the results. METHODS AND FINDINGS: Electronic databases were reviewed from 1946 (Embase) or 1966 (MEDLINE) up to 31 December 2014. Randomized clinical trials (RCTs) of at least 52 wk in duration evaluating second- or third-generation sulfonylureas in the treatment of adults with type 2 diabetes and reporting outcomes of interest were included. Primary outcomes were all-cause and cardiovascular mortality. Additionally, myocardial infarction and stroke events were evaluated. Data were summarized with Peto odds ratios (ORs), and the reliability of the results was evaluated with TSA. Forty-seven RCTs with 37,650 patients and 890 deaths in total were included. Sulfonylureas were not associated with all-cause (OR 1.12 [95% CI 0.96 to 1.30]) or cardiovascular mortality (OR 1.12 [95% CI 0.87 to 1.42]). Sulfonylureas were also not associated with increased risk of myocardial infarction (OR 0.92 [95% CI 0.76 to 1.12]) or stroke (OR 1.16 [95% CI 0.81 to 1.66]). TSA could discard an absolute difference of 0.5% between the treatments, which was considered the minimal clinically significant difference. The major limitation of this review was the inclusion of studies not designed to evaluate safety outcomes. CONCLUSIONS: Sulfonylureas are not associated with increased risk for all-cause mortality, cardiovascular mortality, myocardial infarction, or stroke. Current evidence supports the safety of sulfonylureas; an absolute risk of 0.5% could be firmly discarded. REVIEW REGISTRATION: PROSPERO CRD42014004330.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus
Hemmingsen, B., Schroll, J. B., Lund, S. S., Wetterslev, J., Gluud, C., Vaag, A., Sonne, D. P., Lundstrøm, L. H., & Almdal, T. P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009008.pub2 · Cited by 88 · cited 3×
“These contradictory results may be explained by the inclusion, or not, of first-generation sulfonylureas [19,20], observational studies [21,22], and short-term studies [18–21].”
BackgroundResultRetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 6×
“Therefore, the search strategy included the terms “type 2 diabetes” and “sulfonylureas” and used the recommended, highly sensitive Cochrane Collaboration strategy for RCT systematic reviews [26].”
BackgroundMethodInfluentialDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Research works printed but not linked: 1
- Li MK, Liu Q, Yu ZZ, Cui SM, Shi P, et al (1999) [ Observation of the effect of combination of glipizide and insulin for type2 diabetic patients with secondary failure to oral sulfonylureas]. J Clin Int Med 15: 38.
Cited by
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“[174] Adverse cardiovascular outcomes with sulfonylureas in some observational studies have raised concerns, although findings from recent meta-analysis that included several RCTs reported that sulfonylureas when added to metformin were not associated with allcause mortality and CV mortality.[175] New generation sulfo…”
ResultGenetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
Goodarzi, M. O., & Rotter, J. I. (2020) · Circulation Research · doi:10.1161/circresaha.119.316065 · Cited by 141
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., De Block, C., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 112
“55) compared to metformin, with the exception of one trial comparing sulfonylurea plus metformin to metformin alone, which found no difference in all cause mortality (26).”
BackgroundResultInfluentialGlucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., et al. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_556_17 · Cited by 101
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
Seminer, A., Mulihano, A., O’Brien, C., Krewer, F., Costello, M., Judge, C., O’Donnell, M., & Reddin, C. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0360 · Cited by 91
The role of KATP channels in cerebral ischemic stroke and diabetes
Szeto, V., Chen, N., Sun, H., & Feng, Z. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.10 · Cited by 97
Cardiovascular Protection in People With Diabetes
Stone, J. A., Houlden, R. L., Lin, P., Udell, J. A., & Verma, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.024 · Cited by 83
The role of sulfonylureas in the treatment of type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999413 · Cited by 79
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
Ko, S., Hur, K.-Y., Rhee, S. Y., Kim, N. H., Moon, M. K., Park, S.-O., Lee, B., Kim, H. J., Choi, K. M., & Kim, J. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.337 · Cited by 63
“SUs or DPP4 inhibitors are not associated with increased risks of major cardiovascular events in patients with T2DM, irrespective of comparator or background medications [6,37].”
BackgroundBertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 69
Şahin, İ., Bakıner, O., Demir, T., Sari, R., & Atmaca, A. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01612-8 · Cited by 77
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 65
“Conversely, another recent study, evaluating second- or thirdgeneration sulphonylureas, showed no negative effect with regard of all-cause mortality, cardiac mortality, MI or stroke in patients receiving these molecules (Varvaki Rados et al., 2016).”
BackgroundResultChen, L., Wang, Y., Zhang, T., Li, Y., Meng, T., Liu, L., Hao, R., & Dong, Y. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3055-3 · Cited by 56
Yandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1358064 · Cited by 50
“risk for all-cause mortality, CV mortality, MI, or stroke [46].”
BackgroundShould Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002091 · Cited by 43
Self-citationPro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence
Leonard, C. E., Hennessy, S., Han, X., Siscovick, D. S., Flory, J., & Deo, R. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.04.003 · Cited by 45
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
“effects on SUs on CVD morbidity and mortality as well as allcause death [257], although several previous meta-analyses”
Sulfonylurea and neuroprotection: The bright side of the moon
Al-Kuraishy, H. M., Hussien, N., Al-Naimi, M. S., Rasheed, H., & Al-Gareeb, A. I. (2018) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/japtr.japtr_317_18 · Cited by 42
“It has been mentioned by many researchers the link between SUR and other cardio-metabolic complications which might be falsely positive or negative conclusions since; these contradictory studies explained by short-term or observational studies.[25]”
ResultRSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 57
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 57
Rathmann, W., & Kostev, K. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01943-7 · Cited by 32
“However, as in the present analysis, the effect estimate was slightly increased [29].”
BackgroundResultInfluentialScheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.05.007 · Cited by 37
Association between the ERCC2 Asp312Asn polymorphism and risk of cancer
Xiao, F., Pu, J., Wen, Q., Huang, Q., Zhang, Q., Huang, B., Huang, S., Lan, A., Zhang, Y., Li, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17290 · Cited by 33
“To evaluate whether our meta-analysis had sufficient sample size to reach firm conclusions about the effect of interventions [120], TSA was used in this metaanalysis.”
MethodComparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia
Leonard, C. E., Brensinger, C. M., Aquilante, C. L., Bilker, W. B., Boudreau, D. M., Deo, R., Flory, J., Gagne, J. J., Mangaali, M. J., & Hennessy, S. (2018) · Diabetes Care · doi:10.2337/dc17-0294 · Cited by 37
McCoy, R. G., Herrin, J., Swarna, K. S., Deng, Y., Kent, D. M., Ross, J. S., Umpierrez, G. E., Galindo, R. J., Crown, W. H., Borah, B. J., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00453-9 · Cited by 30
Zaccardi, F., Dhalwani, N. N., Dales, J., Mani, H., Khunti, K., Davies, M. J., & Webb, D. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13185 · Cited by 30
Webb, D. R., Davies, M. J., Jarvis, J., Seidu, S., & Khunti, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107836 · Cited by 36
“Evidence from meta-analyses of studies that were limited to newgeneration Sulphonylureas and those with robust methodological quality indicate no convincing association between all-cause mortality or cardiovascular mortality and Sulphonylurea use in people with Type 2 diabetes [13].”
BackgroundVenkataraman, S., Devarajan, T. V., Kandasamy, N., Oomman, A., Boorugu, H., Karuppiah, S. K. P., & Balat, D. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_176_17 · Cited by 36
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
Quartuccio, M., Buta, B. J., & Kalyani, R. R. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0215-z · Cited by 32
Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes
Razavi-Nematollahi, L., & Ismail‐Beigi, F. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1266-7 · Cited by 33
Bertoluci, M. C., Salles, J. E. N., Silva‐Nunes, J., Pedrosa, H. C., Moreira, R. O., Duarte, R., Carvalho, D. M., Trujilho, F. R., Raposo, J. F. C. D. S., Parente, E. B., et al. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00551-1 · Cited by 33
Self-citationEffects of Naringin on Cardiomyocytes From a Rodent Model of Type 2 Diabetes
Uryash, A., Mijares, A., Flores, V., Adams, J. A., & Lopez, J. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.719268 · Cited by 35
Mannucci, E., Monami, M., Candido, R., Pintaudi, B., & Targher, G. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.032 · Cited by 29
Volke, V., Katus, U., Johannson, A., Toompere, K., Heinla, K., Rünkorg, K., & Uusküla, A. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01158-5 · Cited by 34
“A similar finding was reported at the subgroup analysis in a recent meta-analysis [10].”
BackgroundResultModern Sulfonylureas: Dangerous or Wrongly Accused?
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dci17-0003 · Cited by 27
“Statistical assessments of data pooled from randomized studies and clinical databases continue to be published, with conflicting conclusions (12,13).”
BackgroundA calibration approach to transportability and data‐fusion with observational data
Josey, K., Yang, F., Ghosh, D., & Raghavan, S. (2022) · Statistics in Medicine · doi:10.1002/sim.9523 · Cited by 44
Ko, S., Hur, K. Y., Rhee, S. Y., Kim, N. H., Moon, M. K., Park, S.-O., Lee, B., Kim, H. J., Choi, K. M., & Kim, J. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.298 · Cited by 24
“SUs or DPP4 inhibitors are not associated with increased risks of major cardiovascular events in patients with T2DM, irrespective of comparator or background medications [6,37].”
BackgroundThe Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm
Mohan, V., Cooper, M. E., Matthews, D. R., & Khunti, K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0573-y · Cited by 26
“Another meta-analysis of second- and third-generation SUs that included 47 RCTs of[52 weeks’ duration and a total of 37,650 patients found no increase in all-cause or cardiovascular mortality with SUs as a class, with no differences identified according to follow-up time or whether the SUs were administered as monothe…”
MethodLandgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 24
Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
Thompson, P. L., & Davis, T. M. E. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.10.008 · Cited by 26
Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip
Luconi, M., Cantini, G., Ceriello, A., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.126 · Cited by 24
Acuña, S. A., Dossa, F., & Baxter, N. N. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.05.034 · Cited by 22
Tratamento farmacológico da hiperglicemia no DM2
Filho, R. L. D. S., Albuquerque, L., Cavalcanti, S. M., Tambascia, M. A., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-10 · Cited by 40
The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?
Pop, L. M., & Lingvay, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0954-4 · Cited by 25
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 25
“12,13 Similarly, thiazolidinediones exhibit anti-inflammatory properties and beneficial vascular effects in preclinical trials.”
Santamarina, M. L., & Carlson, C. J. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1036-0 · Cited by 21
Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications
Vaughan, E. M., Rueda, J. J., Samson, S. L., & Hyman, D. J. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200206112318 · Cited by 25
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2020
Orozco‐Beltrán, D., Cuixart, C. B., Sánchez, J. J. A., Banegas, J. R., Cuenca, A. M. C., Gil-Guillén, V. F., Rioboó, E. M., & Pérez, J. N. (2020) · Atención Primaria · doi:10.1016/j.aprim.2020.08.002 · Cited by 30
Monotherapy in Patients with Type 2 Diabetes Mellitus
Rhee, S. Y., Kim, H. J., Ko, S., Hur, K. Y., Kim, N. H., Moon, M. K., Park, S.-O., Lee, B., Choi, K. M., & Kim, J. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.349 · Cited by 25
“A wide variety of previously used drugs such as sulfonylurea, meglitinide, thiazolidinedione, and α-glucosidase inhibitor can also be used as an effective substitute for metformin after securing various evidence on efficacy and safety when using this monotherapy [29,42-44].”
BackgroundKalra, S., Das, A. K., Baruah, M. P., Unnikrishnan, A., Dasgupta, A., Shah, P., Sahay, R. K., Shukla, R., Das, S., TIWASKAR, M. H., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0651-1 · Cited by 22
A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm
Riddle, M. C. (2019) · Diabetes Care · doi:10.2337/dci19-0034 · Cited by 21
Update on Management of Type 2 Diabetes for Cardiologists
Qureshi, M., Gammoh, E., Shakil, J., & Robbins, R. J. (2018) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-14-4-273 · Cited by 19
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022
Orozco‐Beltrán, D., Cuixart, C. B., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Rioboó, E. M., Baldó, A. J., Vicuña, J., & Pérez, J. N. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102444 · Cited by 80
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01121-x · Cited by 25
“• In a meta-analysis [58] of RCTs, CV safety was also extended to glibenclamide (glyburide).”
BackgroundSelf-citationPersonalized Management of Type 2 Diabetes
Peter, P. R., & Lupsa, B. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1244-0 · Cited by 17
Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis
Yen, F., Lai, J., Wei, J. C., Chiu, L., Hwu, C., Hou, M., & Hsu, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243783 · Cited by 19
“Some studies have reported SU use to be associated with increased mortality risk [21, 22], whereas others have reported SU use to not be associated with increased mortality risk [23].”
BackgroundNovel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review
Martínez-Hernández, S. L., Muñoz‐Ortega, M. H., Ávila‐Blanco, M. E., Pizaño, M. Y. M., & Ventura‐Juárez, J. (2023) · Biomedicines · doi:10.3390/biomedicines11102828 · Cited by 19
“Prolonged use of these agents is associated with a progressive reduction in beta cell insulin production, a well-recognized contributor to secondary renal failure (refer to Table 1) [90,91].”
BackgroundDhopeshwarkar, N., Brensinger, C. M., Bilker, W. B., Soprano, S. E., Flory, J., Dawwas, G. K., Gagne, J. J., Hennessy, S., & Leonard, C. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-66668-5 · Cited by 14
Lee, K., Noh, J. H., Park, S., Choi, K. M., Kang, S., Won, K. C., Cho, H., Moon, M. K., & Korean Society of Heart Failure (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0420 · Cited by 14
Cordiner, R. L. M., & Pearson, E. R. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13596 · Cited by 14
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Baccetti, F., Crisafulli, C., Andreozzi, F., Mannino, G. C., Nicolucci, A., Michelli, A., Miranda, C., Candido, R., Bartolo, P. D., Cianni, G. D., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111781 · Cited by 17
Yandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 14
“Another recent meta-analysis of 47 RCTs evaluating second and third generation SUs in T2DM patients showed that SUs were not associated with an increased risk for all-cause mortality, CV mortality, MI, or stroke.(93) Interestingly, a recent metaregression analysis of 19 real-world observational studies showed that SUs…”
ResultEvaluating gliclazide for the treatment of type 2 diabetes mellitus
Tomlinson, B., Li, Y.-H., & Chan, P. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2141108 · Cited by 18
“Another meta-analysis compared clinical trials using second- and third-generation sulfonylureas and other treatments, and found that sulfonylureas were not associated with a significant increase in all-cause mortality, cardiovascular mortality or myocardial infarction [78].”
Diabetes medications and cardiovascular disease: at long last progress
Lupsa, B. C., & Inzucchi, S. E. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000400 · Cited by 12
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Doumas, M. N., & Karagiannis, A. I. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190426162746 · Cited by 13
Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”
Manolis, A. S., Manolis, T. A., & Manolis, A. S. (2018) · Drugs · doi:10.1007/s40265-018-0985-4 · Cited by 12
The complex interplay between diabetes mellitus and atrial fibrillation
Yildiz, M., Lavie, C. J., Morin, D. P., & Oktay, A. A. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2115357 · Cited by 14
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Comoglio, R. H., & Vidal, X. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.11.002 · Cited by 13
Bidulka, P., O’Neill, S., Basu, A., Wilkinson, S., Silverwood, R. J., Charlton, P., Briggs, A. H., Adler, A., Khunti, K., Tomlinson, L. A., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046912 · Cited by 11
Bagepally, B. S., Chaikledkaew, U., Youngkong, S., Anothaisintawee, T., Thavorncharoensap, M., Dejthevaporn, C., & Thakkinstian, A. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s328433 · Cited by 14
Pazoki, M., Chichagi, F., Hadadi, A., Kafan, S., Montazeri, M., Kazemian, S., Aminorroaya, A., Ebrahimi, M., Ashraf, H., Hazaveh, M. M., et al. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00901-4 · Cited by 10
“Meta-analysis of randomized clinical trials suggested that the use of secondand third-generation sulfonylureas in patients with type 2 DM was not associated with increased cardiovascular risk and all-cause mortality, irrespective of comparator or background medication [37].”
Anagnostis, P. G., Siolos, P., Christou, K., Gkekas, N. K., Kosmidou, N., Athyros, V. G., & Karagiannis, A. I. (2018) · HORMONES · doi:10.1007/s42000-018-0017-5 · Cited by 10
Chen, J., Chen, X., Huang, C., Zhu, H., Hou, Z., An, N., Liu, S., Yang, H., & Zhang, C. (2019) · Child s Nervous System · doi:10.1007/s00381-019-04124-0 · Cited by 11
Management of hyperglycaemia in people with obesity
Mourougavelou, V., & Chowdhury, T. A. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0135 · Cited by 11
Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
Sečník, J., Xu, H., Schwertner, E., Hammar, N., Alvarsson, M., Winblad, B., Eriksdotter, M., Ptacek, S. G., & Religa, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215337 · Cited by 11
“Despite some inconsistencies, sulfonylureas did not increase all-cause mortality in the general type 2 diabetes population [8, 38] and the risk of bias among studies very much depend on the comparator and the outcome [39].”
BackgroundKoufakis, T., Dimitriadis, G., & Kotsa, K. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13035 · Cited by 10
“On the other hand, another meta-analysis of randomized trials proved no association between SUs and increased risk for all-cause mortality, CV mortality, myocardial infarction (MI), or stroke, illustrating that available evidence is still insufficient to support definite conclusions.(20) As a result, the conduction of…”
Deng, Y., Polley, E. C., Wallach, J. D., Herrin, J. S., Ross, J. S., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000419 · Cited by 10
Ruiz‐García, A., Arranz-Martínez, E., Merchante, I. M., Fuster, V. P., Tamarit, J. J., Trias, F., Pintó, X., & Ascaso, J. F. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.006 · Cited by 14
Understanding the cardiovascular risk with non-insulin antidiabetic drugs
Athyros, V. G., Imprialos, K. P., Stavropoulos, K., Sahinidis, A., & Doumas, M. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1586881 · Cited by 10
Lee, K., Noh, J. H., Park, S., Choi, K. M., Kang, S., Won, K. C., Cho, H., & Moon, M. K. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0028 · Cited by 8
Monotherapy in patients with type 2 diabetes mellitus
Rhee, S. Y., Kim, H. J., Ko, S., Hur, K. Y., Kim, N. H., Moon, M. K., Park, S.-O., Lee, B., Choi, K. M., & Kim, J. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.312 · Cited by 9
“A wide variety of previously used drugs such as sulfonylurea, meglitinide, thiazolidinedione, and α-glucosidase inhibitor can also be used as an effective substitute for metformin after securing various evidence on efficacy and safety when using this monotherapy [29,42-44].”
BackgroundFederici, M. O., Gentilella, R., Corcos, A., Torre, E., & Genovese, S. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3434 · Cited by 8
Simmons, K., Singh, P. P., Borkar, D. S., Birnbaum, F. A., Thomas, A. S., & Fekrat, S. (2022) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414211063076 · Cited by 8
Shadyab, A. H., Espeland, M. A., Odegaard, A., Manson, J. E., Haring, B., Johnson, K., Chen, Z., Zhang, B., & LaCroix, A. Z. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf095 · Cited by 8
“Meta-analyses have yielded mixed findings on the association of sulfonylureas with all-cause and cardiovascular mortality, with a meta-analysis of RCTs showing that sulfonylureas do not increase mortality risk in individuals with type 2 diabetes (36–38).”
Islam, N., Reynier, P., Douros, A., Yu, O. H. Y., & Filion, K. B. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15000 · Cited by 8
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Rhee, E. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.304 · Cited by 12
“Later studies that included trials of second- and third-generation sulfonylureas did not suggest an overall increased risk of MI or death from CVD [14].”
BackgroundRaghavan, S., Liu, W. G., Saxon, D. R., Grunwald, G. K., Maddox, T. M., Reusch, J. E. B., Berkowitz, S. A., & Caplan, L. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000516 · Cited by 9
From Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care
Shrestha, D., Dhingra, A., Shakya, S., & Tuladhar, J. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01582-6 · Cited by 8
Her, A., Choi, B. G., Rha, S., Kim, Y. H., & Jeong, M. H. (2024) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-23-349 · Cited by 7
“On the contrary, previous meta-analyses evaluating the safety of SU as a group or in combination with MET did not show higher risk of mortality or CV events (23,24).”
Metadata
- Authors
- Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L.
- Affiliations
- Universidade Federal do Rio Grande do Sul (BR)
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-12
- Volume
- 13
- Issue
- 4
- Pages
- e1001992
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC4829174
- OpenAlex
- W2341376576
- Cited by
- 143
- References
- 102
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 18 · 2021: 11 · 2020: 20 · 2019: 17 · 2018: 23 · 2017: 24 · 2016: 4
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-06-24)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- sulfonylureas, type 2 diabetes, drug safety, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, trial sequential analysis, sample size adequacy
- MeSH terms
- Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Risk Factors, Sulfonylurea Compounds, Time Factors, Chi-Square Distribution, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.